CPD Events

CPD Mailing List

Sign up to our CPD mailing list in May and you'll also be entered into our draw, where we'll select names to win prizes.

CPD: Mental health needs of LGBTQ+ people and An introduction to Energy Psychology

Monday 6th November 2023 | 7pm to 8pm

CPD event

Myogenes: The role of Pharmacogenetics in Psychiatry

Wednesday 17th March 2021 at 7 pm.

Phoenix Mental Health Services is offering a CPD opportunity with Myogenes about the role of Pharmacogenetics in Psychiatry. This is scheduled to take place over Zoom on Wednesday 17th March 2021 at 7 pm.

Dr Dahlia Hopmeier, who is a part of Myogenes Expert Panel, and the CEO of Myogenes, Clare Brenner, will be hosting this session. They have organised a Q & A to follow their presentation.

Myogenes offer a genetic test that identifies specific genetic markers that can indicate which medications are likely to work as intended, have no effect, or cause adverse side effects. Phoenix Mental Health Services have been offering this genetic testing to our patients since October 2020 and have some remarkable early experience already which makes us very keen to continue using it.

If you are interested in attending this CPD session, please complete this registration form and I will be in contact: https://form.jotform.com/210333595463354

Please feel welcome to pass this email on to any one that you think may be interested.

Note we reserve the right to end the registration for this CPD session if it reaches maximum capacity. We will let you know if this happens.

The clinical application of the genoSCORE polygenic risk assessment to reduce the risk of cognitive decline in patients with early cognitive concerns.

Wednesday 9th June 2021 at 7 pm

After the success of our last CPD event, Phoenix Mental Health Services is offering another CPD opportunity with Cytox about the clinical application of the genoSCORE polygenic risk assessment to reduce the risk of cognitive decline in patients with early cognitive concerns.

This is scheduled to take place over Zoom on Wednesday 9th June 2021 at 7 pm and will be hosted by the CEO of Cytox, Dr Richard Pither. . Please see the invitation above for more information.

Cytox is a UK company which has developed a polygenic risk test, which is CE-marked, and can predict subsequent cognitive decline due to Alzheimer’s disease in subjects with early cognitive impairment. This test may also have applications in identifying those individuals at highest risk of developing cognitive issues following traumatic head injury. Their presentation will be focusing on these two conditions.

If you are interested in attending this CPD session, please complete this registration form and Jasmin, our Research Associate, will be in contact: https://form.jotform.com/210333595463354.

Please feel welcome to pass this email on to any of your colleagues that you think may be interested.

We reserve the right to end the registration for this CPD session if it reaches maximum capacity. We will let you know if this happens.

Name
Phone
Email Address
Message
0 of 350